GRI Bio (GRI) EPS (Basic) Growth (3y) (2023 - 2026)
GRI Bio (GRI) EPS (Basic) Growth (3y) (2023 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Basic) Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 140.22 Bn | 132.37 Bn | 2.84 Bn | 6.85% |
| 2 | Regeneron Pharmaceuticals | 86.29 Bn | 78.30 Bn | 3.93 Bn | 11.71% |
| 3 | Argenx Se | 65.17 Bn | 59.98 Bn | 1.37 Bn | 64.84% |
| 4 | Moderna | 61.38 Bn | 56.24 Bn | 52.00 Mn | 18.44% |
| 5 | BeOne Medicines | 42.18 Bn | 37.09 Bn | 1.53 Bn | 37.21% |
| 6 | Alnylam Pharmaceuticals | 30.99 Bn | 27.68 Bn | 992.69 Mn | 36.73% |
| 7 | BioNTech SE | 28.45 Bn | 10.05 Bn | 668.28 Mn | -26.87% |
| 8 | Insmed | 27.47 Bn | 26.31 Bn | 358.27 Mn | 67.51% |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -38.31% |
| 10 | GRI Bio | 3.09 Mn | 3.09 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 97.46% |
| Dec 31, 2025 | 92.91% |
| Sep 30, 2025 | 87.87% |
| Jun 30, 2025 | 88.91% |
| Mar 31, 2025 | 93.25% |
| Dec 31, 2024 | 88.79% |
| Sep 30, 2024 | 89.15% |
| Jun 30, 2024 | 82.81% |
| Mar 31, 2024 | 84.52% |
| Dec 31, 2023 | 50.94% |
| Sep 30, 2023 | 57.91% |
| Jun 30, 2023 | 34.57% |
| Mar 31, 2023 | 36.51% |